The Lancet Oncology on X: NEW: phase 2 GORTEC 2014-01 TPExtreme trial: TPEx (cetuximab+docetaxel+cisplatin) vs EXTREME (platinum+fluorouracil+cetuximab) in recurrent or metastatic head and neck squamous-cell carcinoma #headandneckcancer

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil

Cetuximab, fluorouracil and cisplatin with or without docetaxel

Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic

Comprehensive review on how platinum- and taxane-based

Systemic Treatment Sequencing and Prediction of First-line Therapy

Avelumab–cetuximab–radiotherapy versus standards of care in

Pembrolizumab vs the EXTREME Regimen in Recurrent or Metastatic

Frontiers Cetuximab-Containing Combinations in Locally Advanced

Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil

GEDEFO on X: Docetaxel can be substituted for 5-FU in combination

Frontiers The Evolving Role of Taxanes in Combination With